These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10955808)

  • 21. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas.
    Minaguchi T; Yoshikawa H; Oda K; Ishino T; Yasugi T; Onda T; Nakagawa S; Matsumoto K; Kawana K; Taketani Y
    Clin Cancer Res; 2001 Sep; 7(9):2636-42. PubMed ID: 11555573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTEN mutations in uterine sarcomas.
    Amant F; de la Rey M; Dorfling CM; van der Walt L; Dreyer G; Dreyer L; Vergote I; Lindeque BG; Van Rensburg EJ
    Gynecol Oncol; 2002 Apr; 85(1):165-9. PubMed ID: 11925138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of PTEN and the 10q23 region in primary prostate carcinomas.
    Feilotter HE; Nagai MA; Boag AH; Eng C; Mulligan LM
    Oncogene; 1998 Apr; 16(13):1743-8. PubMed ID: 9582022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.
    Maxwell GL; Risinger JI; Gumbs C; Shaw H; Bentley RC; Barrett JC; Berchuck A; Futreal PA
    Cancer Res; 1998 Jun; 58(12):2500-3. PubMed ID: 9635567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
    Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
    Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [PTEN coding product: a marker for tumorigenesis and progression of endometrial carcinoma].
    Gao QL; Ye F; Li J; Xing H; Lu YP; Ma D
    Ai Zheng; 2003 Jun; 22(6):640-4. PubMed ID: 12948417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of PTEN and PTEN pseudogene in endometrial carcinoma.
    Yokoyama Y; Wan X; Shinohara A; Takahashi S; Takahashi Y; Niwa K; Tamaya T
    Int J Mol Med; 2000 Jul; 6(1):47-50. PubMed ID: 10851265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.
    Konopka B; Janiec-Jankowska A; Paszko Z; Goluda M
    J Cancer Res Clin Oncol; 2004 Feb; 130(2):114-21. PubMed ID: 14663583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Causes and consequences of microsatellite instability in endometrial carcinoma.
    Gurin CC; Federici MG; Kang L; Boyd J
    Cancer Res; 1999 Jan; 59(2):462-6. PubMed ID: 9927063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allelic imbalance and mutations of the PTEN gene in ovarian cancer.
    Saito M; Okamoto A; Kohno T; Takakura S; Shinozaki H; Isonishi S; Yasuhara T; Yoshimura T; Ohtake Y; Ochiai K; Yokota J; Tanaka T
    Int J Cancer; 2000 Jan; 85(2):160-5. PubMed ID: 10629071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inactivation of the PTEN gene by mutation, exonic deletion, and loss of transcript in human oral squamous cell carcinomas.
    Shin KH; Kim JM; Rho KS; Park KH; Oh JE; Min BM
    Int J Oncol; 2002 Nov; 21(5):997-1001. PubMed ID: 12370746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of allelic loss (LOH) in vulvar squamous carcinomas and adjacent noninvasive epithelia.
    Lin MC; Mutter GL; Trivijisilp P; Boynton KA; Sun D; Crum CP
    Am J Pathol; 1998 May; 152(5):1313-8. PubMed ID: 9588899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.
    Mutter GL; Lin MC; Fitzgerald JT; Kum JB; Baak JP; Lees JA; Weng LP; Eng C
    J Natl Cancer Inst; 2000 Jun; 92(11):924-30. PubMed ID: 10841828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Molecular Sequencing of Recurrent and Multifocal Non-HPV-associated Squamous Cell Carcinoma of the Vulva.
    Pors J; Tessier-Cloutier B; Thompson E; Almadani N; Ho J; Gilks B; Huntsman D; Hoang L
    Int J Gynecol Pathol; 2021 Jul; 40(4):391-399. PubMed ID: 33323855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTEN expression in tamoxifen-associated endometrial cancers.
    Holtz D; Ramondetta LM; Burke TW; Palazzo JP; Dunton CJ; Atkinson EN; Broaddus RR
    Anticancer Res; 2002; 22(5):2945-8. PubMed ID: 12530022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas.
    Freihoff D; Kempe A; Beste B; Wappenschmidt B; Kreyer E; Hayashi Y; Meindl A; Krebs D; Wiestler OD; von Deimling A; Schmutzler RK
    Br J Cancer; 1999 Feb; 79(5-6):754-8. PubMed ID: 10070865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases.
    Bussaglia E; del Rio E; Matias-Guiu X; Prat J
    Hum Pathol; 2000 Mar; 31(3):312-7. PubMed ID: 10746673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors.
    Simpkins SB; Peiffer-Schneider S; Mutch DG; Gersell D; Goodfellow PJ
    Gynecol Oncol; 1998 Dec; 71(3):391-5. PubMed ID: 9887237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer.
    Ikeda T; Yoshinaga K; Suzuki A; Sakurada A; Ohmori H; Horii A
    Oncol Rep; 2000; 7(3):567-70. PubMed ID: 10767369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic and genetic alternation of PTEN in cervical neoplasm.
    Cheung TH; Lo KW; Yim SF; Chan LK; Heung MS; Chan CS; Cheung AY; Chung TK; Wong YF
    Gynecol Oncol; 2004 Jun; 93(3):621-7. PubMed ID: 15196854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.